Biomarker-Based Disease Detection Market: The U.S. at the Center of a Diagnostic Transformation

The biomarker-based disease detection market is entering a decisive growth phase, supported by advances in molecular biology, data analytics, and clinical validation frameworks. This expansion reflects not only rising disease burden but also a structural shift in how healthcare systems approach diagnosis, moving from symptom-driven investigation to proactive, data-rich detection anchored in biological signals.

In the U.S., the key issue is less about the speed of GDP growth and more about a country's overall power. America is a major market actively accelerating this market’s expansion. The relaxed regulatory environment, abundant venture capital, and a high number of biotech companies have created an environment where biomarker innovations transition from the lab to the clinic more rapidly than in nearly any other location worldwide.  

The U.S. Diagnostic Paradigm Is Quietly Being Rewritten

Historically in the U.S., diagnostics has been performed reactively; patients present with symptoms or signs of disease, physicians order an appropriate test(s), and then the patient receives treatment. Using biomarker-based detection, doctors can transform diagnostic practices by utilizing biomarkers to identify diseases before clinical symptoms appear, thus changing the timing of interventions.

Cancer screening offers a clear illustration. Multi-cancer early detection (MCED) tests, built on circulating tumor DNA (ctDNA) biomarkers, are pushing diagnostics into asymptomatic populations. This is not just a technological shift it’s a philosophical one. The healthcare system must now grapple with identifying disease risk rather than confirmed disease. In 2025, 2,041,910 new cancer cases and 618,120 cancer deaths are projected to occur in the United States as per American Cancer Society. 

That introduces complexity. Earlier detection is valuable, but it also raises questions around overdiagnosis, cost-effectiveness, and clinical pathways. The U.S. system, with its mix of private insurers and public programs like Medicare, is uniquely positioned to test how these challenges can be resolved at scale.

Guardant Health, Inc., a pioneer in precision oncology, announced a multi-year partnership with Nuvalent, Inc., a clinical-stage biopharmaceutical company that develops precisely targeted treatments for clinically validated kinase targets in cancer, to provide the development and potential commercialization of Nuvalent's oncology pipeline using the tissue and liquid products of the Guardant Infinity™ platform. The collaboration highlights the increasing role of precision diagnostics in oncology drug development, for biomarker-driven strategies are becoming more crucial generally to identify suitable populations, make trials more efficient and obtain regulatory approvals.

Why Biomarkers Are Becoming Central to U.S. Healthcare Economics

Biomarkers are no longer the exclusive domain of research labs. They are becoming an integral part of clinical decision-making, primarily in cancer, brain diseases, and heart conditions. The main factor behind the U.S. adoption of this trend is economics as much as the scientific aspect.

Healthcare payers are being forced to find ways to lower their costs over a longer term. Biomarkers provide early detection that can change the market, catching the disease at an earlier stage, treating it better, and not having to go through the very costly pay for late-stage interventions. Nevertheless, the initial cost of biomarker tests, especially advanced genomic assays, is still high.

It is quite interesting that value-based care models are leading to even faster adoption. When healthcare providers' rewards depend on improved results and not the number of visits, early detection tools can really play an important role. Biomarkers are quite in line with such a model.

Over the last ten years, government expenditures on federal health programs have increased by 80%, rising from $1.0 trillion in 2016 to $1.8 trillion in 2025. Forecast spending is anticipated to increase by 63% in 2036 to $3.1 trillion. In terms of the economy, the portion of spending has increased from 5.4% of Gross Domestic Product (GDP) in 2016 to 6.0% in 2025 and it is expected to reach 6.7% of GDP by 2036.

Technology Convergence Is Driving Innovation

Biomarkers have transcended their original discipline of study and can now be found at the intersection of many scientific fields including genomics, proteomics, metabolomics and increasingly, artificial intelligence (AI). This intersection can currently be seen in the U.S. market as AI-based biomarker discovery is shortening the timeline of drug development. Instead of spending years trying to identify candidate biomarkers based on established hypothesis, machine learning (ML) algorithms have the potential to identify candidate biomarkers from large datasets in a fraction of the time.

While ML technology will help identify many candidate biomarkers, it will not always lead to clinical validation for all candidate biomarkers. In addition to AI-based biomarker validation, liquid biopsy technology is also an area of great interest. With liquid biopsy technology, biomarkers can be identified using a quick, non-invasive test, providing an alternative to the invasive tissue biopsy procedure.

Many companies throughout the United States are investing significant resources in this area because they see this to conduct more extensive routine screening. Finally, digital biomarkers, which are derived primarily from a combination of wearable devices and mobile health data, are emerging as a completely new category of biomarkers that complement the existing biomarkers. While still relatively young, these new categories of digital biomarkers present the opportunity to identify disease continuously soon as opposed to only occasionally.

Quanterix Corporation, a company driving the scientific discovery with ultrasensitive biomarker detection, declared that they are the first to the market, commercially launching two new phospho-tau assays: p?Tau 205 and p?Tau 212, broadening its top-tier portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration.

Regulatory Environment: A Double-Edged Sword

The U.S. regulatory landscape plays a critical role in shaping the biomarker market. The Food and Drug Administration (FDA) has shown increasing openness to innovative diagnostic approaches, particularly in areas of unmet medical need.

Programs such as Breakthrough Device designation have accelerated the approval process for certain biomarker-based tests. This has encouraged investment and experimentation. However, regulatory uncertainty remains, especially around laboratory-developed tests (LDTs).

Stricter oversight could improve quality and consistency, but it may also slow innovation. Smaller biotech firms, which are often the source of breakthrough ideas, could face higher compliance costs. The balance between regulation and innovation is still evolving, and its outcome will significantly influence market dynamics.

Roche has revealed that the United States Food and Drug Administration (FDA) has approved their Elecsys pTau181 test. This is currently the only blood-based biomarker (BBM) test that is officially recognized as an aid for the initial assessment of Alzheimer's disease and other causes of cognitive decline in a primary healthcare setting. The Elecsys pTau181 test is designed for individuals aged 55 and above who are showing signs, symptoms, or have concerns about cognitive decline. It detects phosphorylated Tau (pTau) 181 protein in human plasma, which is a crucial biomarker for Alzheimer's disease, including both amyloid plaque and tau aggregate pathology.

Clinical Adoption: Progress with Friction

Despite technological advances, clinical adoption of biomarker-based detection is not uniform across the U.S. Large academic medical centers tend to be early adopters, integrating advanced diagnostics into patient care. Community hospitals and smaller practices, however, often lag behind.

Several factors contribute to this gap. Cost is one, but so is familiarity. Physicians need to understand how to interpret biomarker results and integrate them into treatment decisions. This requires education and, in some cases, changes to clinical workflows.

There is also the question of evidence. Clinicians are understandably cautious. They want robust data demonstrating that biomarker-based detection improves outcomes. While such evidence is growing, it is not yet comprehensive across all disease areas.

The Alzheimer's Drug Discovery Foundation (ADDF) announced that they have secured an additional $50 million in funding for the third phase of their Diagnostics Accelerator (DxA), which will bring the total money raised for this initiative to $150 million. Having greatly contributed to the changes in blood-based diagnostics, the DxA will in its next phase work on next-generation biomarkers not only to hasten drug development but also to allow the use of combination therapies.

Competitive Landscape: Innovation Meets Scale

The U.S. biomarker market is characterized by a mix of established diagnostics companies and agile biotech startups. The former bring scale, distribution networks, and regulatory experience. The latter bring innovation and speed.

This dynamic has led to a wave of partnerships and acquisitions. Large companies are increasingly acquiring or collaborating with smaller firms to access novel technologies. This trend is likely to continue as the market matures.

Sysmex Corporation revealed that it has released "HISCL™ p-Tau217 Assay Kit for Research Use, a reagent for research to detect a biomarker, blood p-Tau2172 levels, associated with Alzheimer's disease. After the introduction in Europe, the Product will gradually be made available in Japan, the United States, South Korea, and Taiwan, thereby helping to speed up worldwide data collection for Alzheimer's disease research.

Below are profiles of four notable U.S.focused companies shaping the biomarker-based disease detection space.

Illumina, Inc.

Illumina remains a foundational player in the genomics ecosystem. Its sequencing platforms underpin a significant portion of biomarker discovery and validation efforts. The company’s influence extends beyond hardware; it shapes the economics of sequencing through continuous cost reduction.

In the U.S., Illumina has positioned itself as an enabler of precision medicine. Its collaborations with healthcare providers and research institutions are aimed at integrating genomic data into routine care. While it does not always operate directly in diagnostics, its technologies are essential to the development of biomarker-based tests.

Illumina Inc. revealed the second version of TruSight Oncology 500, its leading cancer research assay product, which provides comprehensive genomic profiling (CGP) to doctors. CGP acts as a vital lever to open the door to the right medicine for the patient by providing a detailed molecular tumor profile that helps labs working on therapy selection and clinical trial eligibility. A new and improved version of TruSight Oncology 500 (TSO 500 v2) provides a simpler sample-to-analysis workflow. The Illumina TruSight™ Oncology 500 v2 research assay is ready to go for the market now with built-in HRD biomarker detection, turnaround time reduction, and lower tissue sample input.

Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is present at almost every stage of the diagnostics value chain, delivering both research equipment and clinical testing solutions. The company is particularly good at integration, presenting end-to-end capabilities that only a handful of competitors can challenge.

In the field of biomarkers, the company is growing its molecular diagnostics product line, mainly focusing on cancer and infectious diseases. Strong ties to hospitals and laboratories allow the company's U.S. branch to quickly release new tests.

Guardant Health, Inc.

Guardant Health stands for the new generation of diagnostics companies putting liquid biopsy at the center of their focus. The company's tests work by analyzing the DNA that tumor cells release into the bloodstream to detect cancer and monitor treatment changes.

Located in California, the firm has played a leading role in the efforts to detect multiple cancers at once. Their method is a part of the bigger trend that involves making diagnostics available at earlier stages of diseases. The upward path of Guardant is a clear indication of the confidence investors have in biomarker-based screening.

Bio-Rad Laboratories, Inc.

With a long history in both diagnostics and life sciences, Bio-Rad is an established presence in the biomarker marketplace through its digital PCR technology, which provides accurate and sensitive detection of nucleic acid material.

In addition, Bio-Rad's U.S. presence is defined by both research and clinical applications. Its tools can be found throughout the biomarker validation process, making Bio-Rad a significant contributor to the biomarker ecosystem, even if it’s not that well known to the end patients.

Product Innovation Snapshot (U.S.-Focused)

These products illustrate a broader pattern: innovation is concentrated in a handful of U.S. biotech hubs, particularly California and Massachusetts. This geographic clustering fosters collaboration but also intensifies competition.

The Role of Data: Opportunity and Constraint

Biomarker detection generates large volumes of data and could be used to improve diagnosis, to provide individualized treatment recommendations, and to advance research. The volume of incoming data presents many challenges related to storage, analysis, and privacy. In the U.S., there is a strong advantage relative to infrastructure and analytics capabilities for large datasets like those created by biomarker testing.

However, regulatory guidelines such as HIPAA impose strict rules on data use and security. Balancing innovation while protecting individual privacy is a continuing challenge that affects the ability to share information. There is also the issue of interoperability in that many electronic health record systems do not use compatible technologies (i.e., they cannot easily share or integrate data). Until there is an efficient means of exchanging and sharing this data, it will be challenging to fully realize the potential of biomarker testing.

Future Outlook: Gradual Normalization, Not Sudden Disruption

It is tempting to view biomarker-based detection as a disruptive force that will rapidly transform healthcare. The reality is more nuanced. Adoption will likely be gradual, shaped by evidence, economics, and clinical practice.

In the U.S., the trajectory will depend on several factors:

• Continued reduction in testing costs

• Expansion of reimbursement coverage

• Accumulation of clinical evidence

• Integration into standard care pathways

A Market Defined by Its Implications

The market for biomarker-based disease detection plays a major role in way diseases are defined, patients are treated, and healthcare resources are distributed.

Among the world's countries the effects are most dramatic in the U.S. Growth of the market is indicative of more than just demand, it reveals a change in thinking. Detection of diseases is becoming crucial, and biomarkers are the main players in this transformation. This change of direction has the potential to produce benefits if it is well implemented. Just having the technology is not sufficient. There is a need for supporting evidence, seamless integration into workflows and economic feasibility.